INT59929

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 60
Total Number 61
Disease Relevance 16.33
Pain Relevance 15.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
Anatomy Link Frequency
liver 5
hepatocytes 1
1A2 1
hearts 1
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 135 100.00 Very High Very High Very High
diclofenac 66 100.00 Very High Very High Very High
fluoxetine 82 99.84 Very High Very High Very High
Dextromethorphan 2 99.04 Very High Very High Very High
sSRI 133 98.66 Very High Very High Very High
methadone 153 98.52 Very High Very High Very High
Inflammation 116 97.22 Very High Very High Very High
antagonist 166 97.00 Very High Very High Very High
Lasting pain 18 96.08 Very High Very High Very High
Paracetamol 16 95.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 138 100.00 Very High Very High Very High
Colon Cancer 8 99.44 Very High Very High Very High
Fungal Infection 7 99.40 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 147 98.36 Very High Very High Very High
Increased Venous Pressure Under Development 59 97.76 Very High Very High Very High
Neutropenia 12 97.12 Very High Very High Very High
Fever 6 96.64 Very High Very High Very High
Diarrhoea 44 96.12 Very High Very High Very High
Pain 100 96.08 Very High Very High Very High
Adenoma 2 95.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both parecoxib and valdecoxib inhibit human cytochrome P450 2C9 (CYP2C9) activity in vitro.
Negative_regulation (inhibit) of CYP2C9
1) Confidence 0.59 Published 2002 Journal Anesthesiology Section Abstract Doc Link 11753007 Disease Relevance 0.09 Pain Relevance 0.09
S-mephenytoin (SMP) (a CYP2C19 substrate) at high concentration and sulfaphenazole (SUL) (a selective inhibitor of CYP2C9) substantially inhibited norfluoxetine formation.
Negative_regulation (inhibitor) of CYP2C9
2) Confidence 0.57 Published 2001 Journal Acta Pharmacol. Sin. Section Body Doc Link 11730569 Disease Relevance 0 Pain Relevance 0
A very weak time-dependent CYP2C9 inhibitor (AZ1, a proprietary AstraZeneca compound; KI 30 microM and kinact 0.02 min(-1)) effectively abolished CYP2C9 activity over 24 h at low (micromolar) concentrations in primary cultured human hepatocytes.
Negative_regulation (abolished) of CYP2C9 in hepatocytes
3) Confidence 0.57 Published 2006 Journal Drug Metab. Dispos. Section Abstract Doc Link 16679385 Disease Relevance 0 Pain Relevance 0.39
It is not an inhibitor of CYP drug metabolizing enzymes but there is potential for suppression of CYP2C9 and CYP3A at concentrations above 10 ?
Negative_regulation (suppression) of CYP2C9
4) Confidence 0.57 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721288 Disease Relevance 1.40 Pain Relevance 0.03
Among them, tanshinone IIA and cryptotanshinone are found to be potent inhibitors to CYP1A2, while artemisinin is a marginal inhibitor to CYP1A2 and glycyrrhetic acid is a weak inhibitor to CYP2C9.
Negative_regulation (inhibitor) of CYP2C9
5) Confidence 0.56 Published 2007 Journal Rapid Commun. Mass Spectrom. Section Abstract Doc Link 17279482 Disease Relevance 0 Pain Relevance 0.20
Fluoxetine and fluvoxamine are moderate inhibitors of CYP2C19 ('S-mephenytoinhydroxylase'), and fluvoxamine might also be a moderate inhibitor of CYP2C9.
Negative_regulation (inhibitor) of CYP2C9 associated with fluoxetine
6) Confidence 0.54 Published 1996 Journal Int Clin Psychopharmacol Section Abstract Doc Link 8732441 Disease Relevance 0 Pain Relevance 0.48
As with other protease inhibitors, atazanavir is also a substrate and moderate inhibitor of the cytochrome P450 (CYP) system, in particular CYP3A4 and CYP2C9.
Negative_regulation (inhibitor) of CYP2C9
7) Confidence 0.53 Published 2004 Journal Pharmacotherapy Section Abstract Doc Link 15585441 Disease Relevance 1.10 Pain Relevance 0.30
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9.
Negative_regulation (inhibitor) of CYP2C9
8) Confidence 0.52 Published 2004 Journal Therapie Section Abstract Doc Link 15199661 Disease Relevance 0 Pain Relevance 0.59
Both parecoxib and valdecoxib inhibit human cytochrome P450 2C9 (CYP2C9) activity in vitro.
Negative_regulation (inhibit) of cytochrome P450 2C9
9) Confidence 0.51 Published 2002 Journal Anesthesiology Section Abstract Doc Link 11753007 Disease Relevance 0.09 Pain Relevance 0.09
Tipranavir is metabolized by cytochrome P450 (CYP) 3A and, when combined with ritonavir in vitro, causes inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in addition to induction of glucuronidase and the drug transporter P-glycoprotein.
Negative_regulation (inhibition) of CYP2C9
10) Confidence 0.51 Published 2007 Journal Pharmacotherapy Section Abstract Doc Link 17542771 Disease Relevance 0.24 Pain Relevance 0.14
Only modest inhibition of CYP3A4, CYP2C9 and CYP2C19 was observed for a few of the analogs.
Negative_regulation (inhibition) of CYP2C9
11) Confidence 0.47 Published 2009 Journal Bioorg. Med. Chem. Section Abstract Doc Link 19683449 Disease Relevance 0 Pain Relevance 0.49
It is a weak inhibitor of CYP2C8, CYP2C19, and CYP2A6, and a mild-to-moderate inhibitor of CYP2C9 at therapeutic concentrations.34,35 Accordingly, fenofibric acid may have the potential to cause various pharmacokinetic drug interactions.
Negative_regulation (inhibitor) of CYP2C9
12) Confidence 0.47 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0.17 Pain Relevance 0
By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
Negative_regulation (defined) of CYP2C9
13) Confidence 0.43 Published 2009 Journal Medicinal chemistry (Sh?riqah (United Arab Emirates)) Section Abstract Doc Link 19442216 Disease Relevance 0 Pain Relevance 0.09
The Indians had a frequency of CYP2C9*2 and *3 similar to Tamilians and Caucasians.
Negative_regulation (frequency) of CYP2C9
14) Confidence 0.42 Published 2006 Journal J Clin Pharm Ther Section Body Doc Link 16635054 Disease Relevance 0 Pain Relevance 0
Further incubations with (i) liver microsomes from 16 individual donors (correlation analysis), (ii) Supersomes trade mark and (iii) selective chemical inhibitors, implicated CYP3A4/5, CYP2B6 and CYP2C9 in the formation of this component.
Negative_regulation (implicated) of CYP2C9 in liver
15) Confidence 0.42 Published 2004 Journal Biopharm Drug Dispos Section Abstract Doc Link 15108219 Disease Relevance 0.13 Pain Relevance 0.20
Chemical inhibitors of CYP2C, 2E1, and 2D6 did not inhibit N-dealkylation of fentanyl and sufentanil.
Negative_regulation (inhibitors) of CYP2C
16) Confidence 0.42 Published 1996 Journal Anesth. Analg. Section Abstract Doc Link 8712396 Disease Relevance 0 Pain Relevance 0.11
Inhibition studies were performed with tolbutamide and sulfaphenazole (respectively the prototype substrate and a selective inhibitor of cytochrome P450TB--CYP2C subfamily), and with phenytoin and (+/-)-warfarin, other proposed substrates of P450TB.
Negative_regulation (inhibitor) of CYP2C
17) Confidence 0.42 Published 1993 Journal Life Sci. Section Abstract Doc Link 8417277 Disease Relevance 0 Pain Relevance 0.13
Hence, there are chances of drug-drug interaction because modulations of isoenzymes involved in metabolism CYP2C9/10 and CYP2C19 which partially inhibited by etoricoxib.
Negative_regulation (metabolism) of CYP2C9
18) Confidence 0.41 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 18443385 Disease Relevance 0.46 Pain Relevance 0.23
For rapid acting inhibitors, such as azamulin/CYP3A4 and tienilic acid/CYP2C9, the IC(50) shifts were similar at both time points suggesting a short maximum pre-incubation time with closely spaced time points for the K(I)/k(inact) assay.
Negative_regulation (inhibitors) of CYP2C9
19) Confidence 0.41 Published 2009 Journal Xenobiotica Section Abstract Doc Link 19255936 Disease Relevance 0 Pain Relevance 0.30
Similarly, sertraline also inhibits the CYP2C subfamily, but no case reports to date have been identified.
Negative_regulation (inhibits) of CYP2C
20) Confidence 0.41 Published 1997 Journal J Clin Psychopharmacol Section Abstract Doc Link 10950473 Disease Relevance 0 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox